Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the WNT pathway

Neoplasia

Volumn 13, Issue 10, 2011, Pages 887-898

  Toyokawa, Gouji ^a,b   Cho, Hyun Soo ^a   Masuda, Ken ^a   Yamane, Yuka ^a   Yoshimatsu, Masanori ^a,b   Hayami, Shinya ^a   Takawa, Masashi ^a   Iwai, Yukiko ^a   Daigo, Yataro ^a,c   Tsuchiya, Eiju ^d,e   Tsunoda, Tatsuhiko ^f   Field, Helen I ^g   Kelly, John D ^g,h   Neal, David E ^g   Maehara, Yoshihiko ^b   Ponder, Bruce A J ^g   Nakamura, Yusuke ^a   Hamamoto, Ryuji ^a,g  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

^f RIKEN   (Japan)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; HISTONE H3; HISTONE LYSINE METHYLTRANSFERASE; SMALL INTERFERING RNA; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; WOLF HIRSCHHORN SYNDROME CANDIDATE 1;

ADVERSE OUTCOME; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER TISSUE; CARCINOGENESIS; CCND1 GENE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL LEVEL; CELL POPULATION; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE; GENE IDENTIFICATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; RISK REDUCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION; WHSC1 GENE; WOLF HIRSCHHORN SYNDROME;

EID: 80054818729     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11048     Document Type: Article

References (63)

1. Jenuwein T and Allis CD (2001). Translating the histone code. Science 293, 1074-1080.
2. Lachner M, O'Carroll D, Rea S, Mechtler K, and Jenuwein T (2001). Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410, 116-120.
3. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, and Nakamura Y (2004). SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6, 731-740.
4. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, and Furukawa Y (2006). Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 97, 113-118.
5. Volkel P and Angrand PO (2007). The control of histone lysine methylation in epigenetic regulation. Biochimie 89, 1-20.
6. Jenuwein T, Laible G, Dorn R, and Reuter G (1998). SET domain proteins modulate chromatin domains in eu- and heterochromatin. Cell Mol Life Sci 54, 80-93.
7. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP, Allis CD, et al. (2000). Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406, 593-599.
8. Stec I, Wright TJ, van Ommen GJ, de Boer PA, van Haeringen A, Moorman AF, Altherr MR, and den Dunnen JT (1998). WHSC1, a 90 kb SET domaincontaining gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet 7, 1071-1082.
9. Nimura K, Ura K, Shiratori H, Ikawa M, Okabe M, Schwartz RJ, and Kaneda Y (2009). A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf- Hirschhorn syndrome. Nature 460, 287-291.
10. Garlisi CG, Uss AS, Xiao H, Tian F, Sheridan KE, Wang L, Motasim Billah M, Egan RW, Stranick KS, and Umland SP (2001). A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription. Am J Respir Cell Mol Biol 24, 90-98.
11. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, and Bergsagel PL (1998). The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92, 3025-3034.
12. Brito JL, Walker B, Jenner M, Dickens NJ, Brown NJ, Ross FM, Avramidou A, Irving JA, Gonzalez D, Davies FE, et al. (2009). MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica 94, 78-86.
13. Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q, Arceci RJ, Matsui W, and Park BH (2008). The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 111, 856-864.
14. Marango J, Shimoyama M, Nishio H, Meyer JA, Min DJ, Sirulnik A, Martinez- Martinez Y, Chesi M, Bergsagel PL, Zhou MM, et al. (2008). The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 111, 3145-3154.
15. Todoerti K, Ronchetti D, Agnelli L, Castellani S, Marelli S, Deliliers GL, Zanella A, Lombardi L, and Neri A (2005). Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma. Br J Haematol 131, 214-218.
16. Angrand PO, Apiou F, Stewart AF, Dutrillaux B, Losson R, and Chambon P (2001). NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 74, 79-88.
17. Kassambara A, Klein B, and Moreaux J (2009). MMSET is overexpressed in cancers: link with tumor aggressiveness. Biochem Biophys Res Commun 379, 840-845.
18. Wallard MJ, Pennington CJ, Veerakumarasivam A, Burtt G, Mills IG, Warren A, Leung HY, Murphy G, Edwards DR, Neal DE, et al. (2006). Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer 94, 569-577.
19. Olsburgh J, Harnden P, Weeks R, Smith B, Joyce A, Hall G, Poulsom R, Selby P, and Southgate J (2003). Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol 199, 41-49.
20. Kato T, Daigo Y, Hayama S, Ishikawa N, Yamabuki T, Ito T, Miyamoto M, Kondo S, and Nakamura Y (2005). A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res 65, 5638-5646.
21. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, et al. (2003). Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22, 2192-2205.
22. Taniwaki M, Daigo Y, Ishikawa N, Takano A, Tsunoda T, Yasui W, Inai K, Kohno N, and Nakamura Y (2006). Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 29, 567-575.
23. Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, and Nakamura Y (2004). ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 10, 8363-8370.
24. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, et al. (2007). Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 67, 11601-11611.
25. Kitahara O, Furukawa Y, Tanaka T, Kihara C, Ono K, Yanagawa R, Nita ME, Takagi T, Nakamura Y, and Tsunoda T (2001). Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res 61, 3544-3549.
26. Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K, Ishikawa O, Ohgaki K, Kashimura N, Miyamoto M, et al. (2004). Genomewide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 23, 2385-2400.
27. Cho HS, Kelly JD, Hayami S, Toyokawa G, Takawa M, Yoshimatsu M, Tsunoda T, Field HI, Neal DE, Ponder BA, et al. (2011). Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia 13, 676-684.
28. Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, et al. (2011). Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 102, 1298-1305.
29. Toyokawa G, Masuda K, Daigo Y, Cho HS, Yoshimatsu M, Takawa M, Hayami S, Maejima K, Chino M, Field HI, et al. (2011). Minichromosome maintenance protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Mol Cancer 10, 65.
30. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, et al. (2011). Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 128, 574-586.
31. Hayami S, Yoshimatsu M, Veerakumarasivam A, Unoki M, Iwai Y, Tsunoda T, Field HI, Kelly JD, Neal DE, Yamaue H, et al. (2010). Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer 9, 59.
32. Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, et al. (2011). Dysregulation of PRMT1 and PRMT6, type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer 128, 562-573.
33. Cho HS, Suzuki T, Dohmae N, Hayami S, Unoki M, Yoshimatsu M, Toyokawa G, Takawa M, Chen T, Kurash JK, et al. (2011). Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res 71, 1-6.
34. Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F, Yoshimoto M, Tsunoda T, Hirata K, and Nakamura Y (2004). Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol 25, 797-819.
35. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, et al. (2005). Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11, 2625-2636.
36. Buongiorno P, Pethe VV, Charames GS, Esufali S, and Bapat B (2008). Rac1 GTPase and the Rac1 exchange factor Tiam1 associate with Wnt-responsive promoters to enhance ß-catenin/TCF-dependent transcription in colorectal cancer cells. Mol Cancer 7, 73.
37. Kuroda S, Fukata M, Nakagawa M, Fujii K, Nakamura T, Ookubo T, Izawa I, Nagase T, Nomura N, Tani H, et al. (1998). Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin-mediated cell-cell adhesion. Science 281, 832-835.
38. Mazieres J, He B, You L, Xu Z, and Jablons DM (2005). Wnt signaling in lung cancer. Cancer Lett 222, 1-10.
39. Minna JD, Roth JA, and Gazdar AF (2002). Focus on lung cancer. Cancer Cell 1, 49-52.
40. Thievessen I, Seifert HH, Swiatkowski S, Florl AR, and Schulz WA (2003). E-cadherin involved in inactivation of WNT/ß-catenin signalling in urothelial carcinoma and normal urothelial cells. Br J Cancer 88, 1932-1938.
41. Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, Tanaka Y, Li LC, Ribeiro-Filho LA, Terashima M, et al. (2006). Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/ß-catenin signaling pathway. Clin Cancer Res 12, 383-391.
42. Yue W, Sun Q, Dacic S, Landreneau RJ, Siegfried JM, Yu J, and Zhang L (2008). Downregulation of Dkk3 activates ß-catenin/TCF-4 signaling in lung cancer. Carcinogenesis 29, 84-92.
43. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S, and Hedge P (1991). Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253, 665-669.
44. Giles RH, van Es JH, and Clevers H (2003). Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653, 1-24.
45. Nusse R (2005). Wnt signaling in disease and in development. Cell Res 15, 28-32.
46. Paul S and Dey A (2008). Wnt signaling and cancer development: therapeutic implication. Neoplasma 55, 165-176.
47. Ohgaki H, Kros JM, Okamoto Y, Gaspert A, Huang H, and Kurrer MO (2004). APC mutations are infrequent but present in human lung cancer. Cancer Lett 207, 197-203.
48. Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N, Ueki M, and Drabkin HA (2001). Mutations of the ß- and γ-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer 85, 64-68.
49. Pokholok DK, Harbison CT, Levine S, Cole M, Hannett NM, Lee TI, Bell GW, Walker K, Rolfe PA, Herbolsheimer E, et al. (2005). Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 122, 517-527.
50. Xiao T, Hall H, Kizer KO, Shibata Y, Hall MC, Borchers CH, and Strahl BD (2003). Phosphorylation of RNA polymerase II CTD regulates H3 methylation in yeast. Genes Dev 17, 654-663.
51. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, and Misteli T (2010). Regulation of alternative splicing by histone modifications. Science 327, 996-1000.
52. Cerveira N, Correia C, Doria S, Bizarro S, Rocha P, Gomes P, Torres L, Norton L, Borges BS, Castedo S, et al. (2003). Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia. Leukemia 17, 2244-2247.
53. Wang GG, Cai L, Pasillas MP, and Kamps MP (2007). NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 9, 804-812.
54. Kim JY, Kee HJ, Choe NW, Kim SM, Eom GH, Baek HJ, Kook H, and Seo SB (2008). Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol Cell Biol 28, 2023-2034.
55. Li Y, Trojer P, Xu CF, Cheung P, Kuo A, Drury WJ III, Qiao Q, Neubert TA, Xu RM, Gozani O, et al. (2009). The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem 284, 34283-34295.
56. Bahmanyar S, Kaplan DD, Deluca JG, Giddings TH Jr, O'Toole ET, Winey M, Salmon ED, Casey PJ, Nelson WJ, and Barth AI (2008). ß-Catenin is a Nek2 substrate involved in centrosome separation. Genes Dev 22, 91-105.
57. Hadjihannas MV, Bruckner M, Jerchow B, Birchmeier W, Dietmaier W, and Behrens J (2006). Aberrant Wnt/ß-catenin signaling can induce chromosomal instability in colon cancer. Proc Natl Acad Sci USA 103, 10747-10752.
58. Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, Heffner A, Will C, Lamy L, Staudt LM, et al. (2011). The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117, 211-220.
59. Morishita M and di Luccio E (2011). Cancers and the NSD family of histone lysine methyltransferases. Biochim Biophys Acta 1816, 158-163.
60. Nimura K, Ura K, and Kaneda Y (2011). Histone methyltransferases: regulation of transcription and contribution to human disease. JMol Med (Berl) 88, 1213-1220.
61. Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F, Bergsagel PL, Wang L, You Z, and Lou Z (2011). MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 470, 124-128.
62. Greiner D, Bonaldi T, Eskeland R, Roemer E, and Imhof A (2005). Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 1, 143-145.
63. Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, Rea S, Mechtler K, Kowalski JA, Homon CA, et al. (2007). Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 25, 473-481.